SEARCH

SEARCH BY CITATION

References

  • 1
    Morris M, Eifel PJ, Lu J et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:113743.
  • 2
    Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:114453.
  • 3
    Keys HM, Bundy BN, Stehman F et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:115461.
  • 4
    Whitney CW, Sause W, Bundy BN et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:133948.
  • 5
    Eifel PJ, Winter K, Morris M et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004;22:87280.
  • 6
    Green JA, Kirwan JM, Tierney JF et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001;358:7816.
  • 7
    Lukka H, Hirte H, Fyles A et al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer—meta-analysis. Clin Oncol 2002;14:20312.
  • 8
    Berman ML, Keys H, Creasman W et al. Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes [a Gynecologic Oncology Group study]. Gynecol Oncol 1984;19:816.
  • 9
    Rotman M, Pajak TF, Choi K et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stage IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. JAMA 1995;274:38793.
  • 10
    Malfetano JH, Keys H, Cunningham MJ et al. Extended field radiation and cisplatin for stage IIB and IIIB cervical carcinoma. Gynecol Oncol 1997;67:2037.
  • 11
    Varia MA, Bundy BN, Deppe G et al. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 1998;42:101523.
  • 12
    Mitsuhashi A, Uno T, Tanaka N et al. Phase I study of daily cisplatin and concurrent radiotherapy in patients with cervical carcinoma. Gynecol Oncol 2005;96:1947.
  • 13
    Grigsby PW, Heydon K, Mutch DG et al. Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys 2001;51:9827.
  • 14
    Sood BM, Timmins PF, Gorla GR et al. Concomitant cisplatin and extended field radiation therapy in patients with cervical and endometrial cancer. Int J Gynecol Cancer 2002;12:45964.
  • 15
    Grigsby PW, Lu JD, Mutch DG et al. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: phase II study of the Radiation Therapy Oncology Group 92-10. Int J Radiat Oncol Biol Phys 1998;41:81722.
  • 16
    Chung Y-L, Jian JJ, Cheng SH et al. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study. Gynecol Oncol 2005;97:12635.
  • 17
    Ang KK. Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects? J Clin Oncol 2004;22:46579.
  • 18
    Portelance L, Chao KS, Grigsby PW et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys 2001;51:2616.
  • 19
    Salama JK, Mundt AJ, Roeske J et al. Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies. Int J Radiat Oncol Biol Phys 2006;65:11706.
  • 20
    Gerszten K, Colonello K, Heron DE et al. Feasibility of concurrent cisplatin and extended field radiation therapy (EFRT) using intensity-modulated radiotherapy (IMRT) for carcinoma of the cervix. Gynecol Oncol 2006;102:1828.
  • 21
    Van Den Berg HA, Olofsen-van Acht MJJ, Van Santvoort JP et al. Definition and validation of a reference target volume in early stage node-positive cervical carcinoma, based on lymphangiograms and CT-scans. Radiother Oncol 2000;54:16370.
  • 22
    Chao KS, Lin M. Lymphangiogram-assisted lymph node target delineation for patients with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002;54:114752.
  • 23
    Taylor A, Rockall AG, Reznek RH et al. Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:160412.